In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
about
Cabozantinib for progressive metastatic medullary thyroid cancer: a reviewWill the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical useSelection and evaluation of new reference genes for RT-qPCR analysis in Epinephelus akaara based on transcriptome dataA phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.Cabozantinib: a review of its use in patients with medullary thyroid cancer.Novel therapies for thyroid cancer.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Cabozantinib in the treatment of hepatocellular carcinoma.A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.Cabozantinib for the treatment of kidney cancer.Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.Cabozantinib in genitourinary malignancies.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.Regulation of MET-mediated proliferation of thyroid carcinoma cells by miR-449b.Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.Cabozantinib for the treatment of renal cell carcinoma.Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.Personalization of targeted therapy in advanced thyroid cancer.Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Identification of novel diagnostic biomarkers for thyroid carcinoma.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Osteonecrosis of the jaw in a patient receiving cabozantinib.
P2860
Q26851709-1B63F658-CA93-4C6A-83E1-A054BC1EE4A5Q27023383-3E1BA919-D74A-45A5-B7AC-671C710C1F1AQ27853074-3FD841C7-BE9A-4B6B-9ACE-F6B237FBE59FQ28541231-31B8B887-8FF6-4185-8D3E-BEA1BF2CFE12Q31160716-49F24DB5-A5F5-4D73-9271-FF883F27A9FBQ33599860-30EEDF2E-D629-457B-8A1C-F84C333DED6AQ34131012-F68456D0-0E59-45F4-88A3-FD8E2D0095BCQ37009001-19C25AB1-F5D7-4F07-9497-34C8B59057EAQ38233319-20EBFE2E-912D-401D-B703-EC2EA0808FA5Q38260495-9CC81938-30BA-4DA2-B00F-1192A61EC9F5Q38552109-2294452F-2105-4A95-923F-F2A897799947Q38625034-75D59926-EBE0-4C5D-9B08-3BC921EA3D28Q38658285-566004B6-C82A-4D43-B103-877FBCDFD4A0Q38661997-36F797DF-B617-4D39-9C20-3C96727F2CCFQ38668871-5F5835AD-05B2-4C91-BA3D-A36CA2C737C5Q38725367-88D5316A-FFAE-4FAE-B5B7-0E2AD3668F9FQ38795560-55F7CED2-E0B8-488D-A016-811FA1972870Q38835745-2822B726-8880-438C-A708-BD99E28AA3B2Q38848483-00BDFE13-9F17-4422-9C3D-FB9C5832E166Q38867413-884447D7-A23C-49D7-BB23-AF538B564875Q38979283-43B82099-EA02-4F48-8BF8-31D3F38AB17BQ39005403-67FAA36A-3B55-4CC2-A726-F84B241BE576Q40112666-3D0972B5-5255-46D9-A081-07B4AAC62E91Q40922523-5421FE18-DF59-4EFD-BD49-78CD11B8DF7EQ41906937-B43D7B0E-3D7D-449C-9C7E-DB06EC5AFE9AQ45998322-28A6AC5E-625B-4A20-9C2B-DEAF9F96049EQ47116036-81BE3A5D-894C-43AE-90A5-F9751C1610A8Q47601932-EFDDC1A8-7A9F-4008-A555-4D9919008A18Q49010203-FDA43315-0A70-4DBF-B63A-E0BF664C23F4Q49887893-421886D5-BD43-44F7-B85B-621A9CEBDFB0Q50017200-09FE0165-A444-4D90-AE12-8755EB99D121Q50085302-F4EADC41-D7D0-452D-BCAB-8E5500EDDF06Q51071178-CC9EEDC4-3F38-4F55-92EF-460C7831E007
P2860
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@en
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@nl
type
label
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@en
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@nl
prefLabel
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@en
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@nl
P2093
P2860
P356
P1433
P1476
In vitro and in vivo activity ...... l of medullary thyroid cancer.
@en
P2093
Alison H Joly
Anna Gibson
Belinda Cancilla
Donghui Huang
F Michael Yakes
Frauke Bentzien
Leanne Goon
Marcus Zuzow
P2860
P304
P356
10.1089/THY.2013.0137
P577
2013-09-17T00:00:00Z